Jasper Therapeutics, Inc. (JSPR) — Analyst outlook / Analyst consensus target is. Based on 12 analyst ratings, the consensus is bullish — 8 Buy, 4 Hold.
The consensus price target is $41.67 (low: $3.00, high: $65.00), representing an upside of 4369.1% from the current price $0.93.
Analysts estimate Earnings Per Share (EPS) of $-4.54 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-4.89 vs est $-4.54 (missed -7.8%). 2025: actual $-3.95 vs est $-4.71 (beat +16.2%). Analyst accuracy: 87%.
JSPR Stock — 12-Month Price Forecast
$41.67
▲ +4,369.11% Upside
Average Price Target
Based on 12 Wall Street analysts offering 12-month price targets for Jasper Therapeutics, Inc., the average price target is $41.67, with a high forecast of $65.00, and a low forecast of $3.00.
The average price target represents a +4,369.11% change from the last price of $0.93.
Highest Price Target
$65.00
Average Price Target
$41.67
Lowest Price Target
$3.00
JSPR Analyst Ratings
Buy
Based on 12 analysts giving stock ratings to Jasper Therapeutics, Inc. in the past 3 months
EPS Estimates — JSPR
87%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$4.89
vs Est –$4.54
▼ 7.2% off
2025
Actual –$3.95
vs Est –$4.71
▲ 19.3% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — JSPR
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
